New combo aims to stall advanced breast cancer

NCT ID NCT03393845

Ongoing Disease control Sponsor: Nancy Chan, MD Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the hormone therapy fulvestrant (Faslodex) can help control advanced or metastatic breast cancer that is hormone receptor positive and HER2 negative. The study includes 47 adults and measures how many patients have their cancer shrink or stay stable for at least four months. The goal is disease control, not a cure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pembrolizumab (Keytruda) and fulvestrant (Faslodex)
What this could lead to: If successful, this combination could offer a new treatment option to slow or stop advanced breast cancer growth in patients who have limited choices.
What could go wrong: This is a small, early-phase trial with only 47 participants. The drugs may cause serious side effects, and the benefit may not be confirmed in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Locations

Michigan State University, Breslin Cancer Center

Lansing, Michigan, 48910, United States
New York University Clinical Cancer Center

New York, New York, 10016, United States
Rutgers Cancer Institute of New Jersey

New Brunswick, New Jersey, 08903, United States
University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States
University of Wisconsin

Madison, Wisconsin, 53705, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.